Kerri Fitzgerald

DocwireNews

The&nbsp;phase III&nbsp;SOLO1 study&nbsp;found that&nbsp;maintenance&nbsp;olaparib provided a substantial progression-free survival&nbsp;benefit in&nbsp;women with newly diagnosed advanced ovarian cancer and a&nbsp;BRCA1/2&nbsp;mutation, according to research presented at the ESMO&nbsp;2018 annual&nbsp;meeting and subsequently published in the&nbsp;New England Journal of Medicine.&nbsp;The&nbsp;international, randomized, double-blind trial&nbsp;evaluated maintenance&nbsp;olaparib&nbsp;in patients with&nbsp;high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer with a mutation in&nbsp;BRCA1,&nbsp;BRCA2, or both who had a complete or partial clinical response after platinum-based chemotherapy.&nbsp;Patients&nbsp;(n=391)&nbsp;were&nbsp;randomized&nbsp;2:1&nbsp;to receive olaparib 300 mg twice daily&nbsp;(n=260)&nbsp;or placebo&nbsp;(n=131).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
RT Aiims1742: Well done trial in an appropriately defined genetic subset &#128073;&#127998; PFS data you can &ldquo;drive a truck through&rdquo; (phrase courtesy of mcquadeMDLAc) Also lesson learned &#128073;&#127998; PARP inh should be used earlier in disease, not after platinum resistance has se&hellip; <a href="https://t.co/3QkPiXPrrD">https://t.co/3QkPiXPrrD</a>
&mdash; James Suliburk (@jsuliburk) <a href="https://twitter.com/jsuliburk/status/1054352530661085185?ref_src=twsrc%5Etfw">October 22, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>After a median follow-up of 41 months, the risk of disease progression or death was 70% lower with olaparib than placebo. The estimated&nbsp;rate of freedom from disease progression&nbsp;or death at 3 years was&nbsp;60%&nbsp;in the olaparib cohort and&nbsp;27%&nbsp;in the placebo cohort (hazard ratio&nbsp;=&nbsp;0.30; 95%&nbsp;CI, 0.23-0.41;&nbsp;P&lt;0.001).&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Well done trial in an appropriately defined genetic subset &#128073;&#127998; PFS data you can &ldquo;drive a truck through&rdquo; (phrase courtesy of <a href="https://twitter.com/mcquadeMDLAc?ref_src=twsrc%5Etfw">@mcquadeMDLAc</a>) Also lesson learned &#128073;&#127998; PARP inh should be used earlier in disease, not after platinum resistance has set in. Eagerly awaiting POLO data. <a href="https://t.co/i9Vf7hh1Ja">https://t.co/i9Vf7hh1Ja</a>
&mdash; Anirban Maitra (@Aiims1742) <a href="https://twitter.com/Aiims1742/status/1054021344856281088?ref_src=twsrc%5Etfw">October 21, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Adverse events&nbsp;associated with olaparib were consistent with previous reports.&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/nsaid-improves-ovarian-cancer/">NSAID use improves ovarian cancer survival.</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/decreased-risk-ovarian-cancer/">Certain birth control is associated with a decreased risk of ovarian cancer.</a>Source:&nbsp;<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1810858">New England Journal of Medicine</a>

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Olaparib Provides Substantial PFS Benefit for Ovarian Cancer

Ovarian Cancer

The phase III SOLO1 study found that maintenance olaparib provided a substantial progression-free survival benefit in women with newly diagnosed advanced ovarian cancer ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe